{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:11:51Z","timestamp":1793502711324,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon 2020","doi-asserted-by":"publisher","award":["965265"],"award-info":[{"award-number":["965265"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijid.2025.108305","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T23:21:53Z","timestamp":1765063313000},"page":"108305","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study"],"prefix":"10.1016","volume":"163","author":[{"given":"Matteo","family":"Augello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Varisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Timelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bartoletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonfanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Bussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Cattelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Codeluppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Frallonardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Franzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Gattuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Iaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Meschiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Monari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Mularoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Piconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pipitone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Rizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Rusconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Sanguinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Saracino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Tagliaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Torti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Visicaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4828","authenticated-orcid":false,"given":"Giulia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijid.2025.108305_bib0001","article-title":"Cefiderocol: Systematic review of mechanisms of resistance, heteroresistance and In vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijid.2025.108305_bib0002","article-title":"Cefiderocol for the treatment of multidrug-resistant gram-negative bacteria: a systematic review of currently available evidence","volume":"13","author":"Wang","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ijid.2025.108305_bib0003","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/cid\/ciab757","article-title":"Cefiderocol: a new cephalosporin stratagem against multidrug-resistant gram-negative bacteria","volume":"74","author":"Ong'uti","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2025.108305_bib0004","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2025.108305_bib0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"10.1016\/j.ijid.2025.108305_bib0006","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase-producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2025.108305_bib0007","article-title":"Cefiderocol versus standard therapy for hospital-acquired and health-care-associated gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial","author":"Paterson","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2025.108305_bib0008","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence","volume":"13","author":"Viale","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"3","key":"10.1016\/j.ijid.2025.108305_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.01.012","article-title":"Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis","volume":"88","author":"Onorato","year":"2024","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.ijid.2025.108305_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.107047","article-title":"Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: a systematic review with meta-analysis","volume":"63","author":"Gatti","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.ijid.2025.108305_bib0011","article-title":"Cefiderocol versus best available therapy in the treatment of critically ill patients with severe infections due to resistant gram-negative bacteria: a systematic review and meta-analysis","volume":"13","author":"Risco-Risco","year":"2024","journal-title":"Antibiotics (Basel)"},{"issue":"6","key":"10.1016\/j.ijid.2025.108305_bib0012","article-title":"Effectiveness of first-line therapy with old and novel antibiotics in ventilator-associated pneumonia caused by carbapenem-resistant","volume":"12","author":"Dalfino","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijid.2025.108305_bib0013","unstructured":"MJ Asensio Martin, A Bleibtreu, E Durante-Mangoni, D Wichmann, DW Wareham, OA Cornely, , et al, Cefiderocol treatment in patients with gram-negative bacterial infections: European results of the global retrospective observational PROVE study. ESCMID Global 2025 (Poster #2542). Available at: https:\/\/shionogimedical.com\/s3fs\/s3fs-public\/2025-04\/Cefiderocol%20treatment%20in%20patients%20with%20Gram_negative%20bacterial%20infections%20European%20results%20of%20the%20global%20retrospective%20observational%20PROVE%20study.pdf?VersionId=4tf1IaLy3PI_wyK4nrk3fjIV1VXQWSwH [accessed September 1, 2025]."},{"issue":"5","key":"10.1016\/j.ijid.2025.108305_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.ijid.2025.108305_bib0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"8","key":"10.1016\/j.ijid.2025.108305_bib0016","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ijid.2025.108305_bib0017","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1109\/TVCG.2014.2346248","article-title":"UpSet: visualization of intersecting sets","volume":"20","author":"Lex","year":"2014","journal-title":"IEEE Trans Vis Comput Graph"},{"issue":"4","key":"10.1016\/j.ijid.2025.108305_bib0018","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3390\/microorganisms11040984","article-title":"Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant","volume":"11","author":"Mazzitelli","year":"2023","journal-title":"Microorganisms"},{"issue":"6","key":"10.1016\/j.ijid.2025.108305_bib0019","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10096-024-04833-8","article-title":"Clinical effectiveness of cefiderocol for the treatment of bloodstream infections due to carbapenem-resistant Acinetobacter baumannii during the COVID-19 era: a single center, observational study","volume":"43","author":"Oliva","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2025.108305_bib0020","doi-asserted-by":"crossref","first-page":"dlad085","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant","volume":"5","author":"Rando","year":"2023","journal-title":"JAC Antimicrob Resist"},{"issue":"8","key":"10.1016\/j.ijid.2025.108305_bib0021","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol versus Colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.ijid.2025.108305_bib0022","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1186\/s12879-024-09899-5","article-title":"Comparison of cefiderocol and colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review with meta-analysis and trial sequential analysis","volume":"24","author":"Zhan","year":"2024","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.ijid.2025.108305_bib0023","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.ijid.2025.108305_bib0024","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant gram-negative bacteria: an Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"10.1016\/j.ijid.2025.108305_bib0025","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.ijid.2025.108305_bib0026","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.03108-23","article-title":"Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections","volume":"12","author":"El Ghali","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"4","key":"10.1016\/j.ijid.2025.108305_bib0027","article-title":"Cefiderocol efficacy in a real-life setting: single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijid.2025.108305_bib0028","unstructured":"ECDC\/WHO, Antimicrobial resistance surveillance in Europe 2023\u20132021 data. ECDC\/WHO"},{"issue":"7","key":"10.1016\/j.ijid.2025.108305_bib0029","doi-asserted-by":"crossref","first-page":"ofad329","DOI":"10.1093\/ofid\/ofad329","article-title":"Carbapenem-resistant","volume":"10","author":"Giannella","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2025.108305_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2025.108305_bib0031","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ijid.2025.108305_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106611","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"10.1016\/j.ijid.2025.108305_bib0033","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dkaf306","article-title":"Synergistic cefiderocol-containing antibiotic combinations active against highly drug-resistant Acinetobacter baumannii patient isolates with diverse resistance mechanisms","volume":"80","author":"Halim","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.ijid.2025.108305_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106376","article-title":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges","year":"2025","journal-title":"J Infect"},{"issue":"27","key":"10.1016\/j.ijid.2025.108305_bib0035","doi-asserted-by":"crossref","first-page":"12519","DOI":"10.1039\/D5SC02122G","article-title":"Cefiderocol ``under siege''? Understanding the rise of NDM-mediated resistance to novel agents","volume":"16","author":"Warecki","year":"2025","journal-title":"Chem Sci"},{"key":"10.1016\/j.ijid.2025.108305_bib0036","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225005272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971225005272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:46:47Z","timestamp":1783018007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971225005272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"alternative-id":["S1201971225005272"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108305","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of cefiderocol as monotherapy or combination therapy for the treatment of Gram-negative bacterial infections: the multicentre retrospective CEFI-BAC study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2025.108305","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108305"}}